Table 1 Demographic data and characteristics of the study cohort
Variable | Full sample | Erenumab | Galcanezumab/ Fremanezumab |
|---|---|---|---|
n | 39 | 16 | 23 |
Sex (female) | 37 (94.9) | 15 (93.8) | 22 (95.7) |
Age (years) | 51.2 ± 11.1 | 52.3 ± 12.3 | 50.5 ± 10.4 |
Chronic migraine | 25 (64.1) | 10 (62.5) | 15 (65.2) |
With aura | 20 (51.3) | 8 (50.0) | 12 (52.2) |
Months of treatment prior to discontinuation | 9.5 ± 1.0 | 9.9 ± 1.5 | 9.3 ± 0.4 |